Pages that link to "Q33365279"
Jump to navigation
Jump to search
The following pages link to Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation (Q33365279):
Displaying 50 items.
- MiR-185 Targets the DNA Methyltransferases 1 and Regulates Global DNA Methylation in human glioma (Q21245768) (← links)
- Decitabine in the treatment of myelodysplastic syndromes (Q24641906) (← links)
- Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma (Q26851166) (← links)
- DNA demethylation and invasive cancer: implications for therapeutics (Q27011914) (← links)
- A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer (Q33267359) (← links)
- Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study (Q33390459) (← links)
- Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). (Q33416734) (← links)
- Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. (Q33621141) (← links)
- Demethylating Agents in the Treatment of Cancer (Q33678040) (← links)
- Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report (Q33744733) (← links)
- LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors (Q33763848) (← links)
- Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer (Q33782392) (← links)
- Aberrant DNA methylation in malignant melanoma (Q34516587) (← links)
- Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety (Q34557714) (← links)
- Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine. (Q34622598) (← links)
- Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies (Q34768789) (← links)
- Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. (Q35563726) (← links)
- Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method (Q35781849) (← links)
- Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy. (Q35827602) (← links)
- A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy (Q35968482) (← links)
- The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression (Q35985465) (← links)
- Epigenetic alterations in bladder cancer and their potential clinical implications. (Q36095721) (← links)
- Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts (Q36214731) (← links)
- DNA methylation: its role in lung carcinogenesis and therapeutic implications (Q36235566) (← links)
- Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia (Q36238674) (← links)
- Epigenetic therapy of cancer: past, present and future (Q36399557) (← links)
- The role of decitabine in the treatment of myelodysplastic syndromes (Q36681327) (← links)
- Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. (Q36801625) (← links)
- Epigenetic resensitization to platinum in ovarian cancer (Q36979382) (← links)
- DNA methylation: its role in cancer development and therapy (Q36986433) (← links)
- Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias (Q37184917) (← links)
- The CpG island in the murine foxl2 proximal promoter is differentially methylated in primary and immortalized cells (Q37211160) (← links)
- Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer (Q37585487) (← links)
- Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines (Q37645183) (← links)
- The epigenome as a therapeutic target in prostate cancer (Q37808106) (← links)
- Hypomethylating Agents for Urologic Cancers (Q37854737) (← links)
- Epigenetics in Prostate Cancer: Biologic and Clinical Relevance (Q37896315) (← links)
- The application of delivery systems for DNA methyltransferase inhibitors (Q37911496) (← links)
- Epigenetic alterations in osteosarcoma: promising targets (Q38185555) (← links)
- Epigenetic changes in gastroenteropancreatic neuroendocrine tumours (Q38272919) (← links)
- Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer (Q38529787) (← links)
- Methylation Status of the RIZ1 Gene Promoter in Human Glioma Tissues and Cell Lines (Q38739735) (← links)
- A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer (Q39450048) (← links)
- MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing (Q39533432) (← links)
- Additive effects of 5-aza-2'-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines (Q39851827) (← links)
- DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. (Q40054309) (← links)
- The synergistic effect of 5-aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors (Q40095644) (← links)
- Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. (Q40149920) (← links)
- Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma (Q40262211) (← links)
- 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation (Q40262851) (← links)